JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Penumbra Inc

Затворен

СекторЗдравеопазване

339.22 -0.18

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

337.65

Максимум

340.72

Ключови измерители

By Trading Economics

Приходи

581K

46M

Продажби

15M

355M

P/E

Средно за сектора

85.404

84.243

Марж на печалбата

12.927

Служители

4,500

EBITDA

4M

55M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+8.66% upside

Дивиденти

By Dow Jones

Следващи печалби

17.02.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

5.2B

14B

Предишно отваряне

339.4

Предишно затваряне

339.22

Настроения в новините

By Acuity

94%

6%

334 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Penumbra Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.01.2026 г., 13:29 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update

15.01.2026 г., 12:35 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- Update

15.01.2026 г., 12:29 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

24.01.2026 г., 06:18 ч. UTC

Придобивния, сливания и поглъщания

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

15.01.2026 г., 14:37 ч. UTC

Горещи акции

Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock -- WSJ

15.01.2026 г., 13:45 ч. UTC

Придобивния, сливания и поглъщания

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. -- Barrons.com

15.01.2026 г., 12:04 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific: Penumbra Shareholders Can Elect to Receive Cash or Stock >BSX PEN

15.01.2026 г., 12:03 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific: Acquisition to Expand Cardiovascular Portfolio >BSX PEN

15.01.2026 г., 12:01 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific: Penumbra Deal Carriers an Enterprise Value of About $14.5 Billion >BSX

15.01.2026 г., 12:00 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Penumbra for $374/Share >BSX PEN

15.01.2026 г., 12:00 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific Announces Agreement To Acquire Penumbra, Inc. >BSX PEN

Сравнение с други в отрасъла

Ценова промяна

Penumbra Inc Прогноза

Ценова цел

By TipRanks

8.66% нагоре

12-месечна прогноза

Среден 370.55 USD  8.66%

Висок 374 USD

Нисък 340 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Penumbra Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

15 ratings

3

Купи

12

Задържане

0

Продай

Техническа оценка

By Trading Central

288.28 / 292.9394Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Weak Bullish Evidence

Настроение

By Acuity

334 / 352 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat